Abstract
Sickle cell disease is a non-communicable disease attracting global public health concern. Chronic effects of sustained hemolytic anemia drive the development of end-organ complications which include heart, brain, kidney, and bones as sickle cell disease patients live longer. Cardiovascular dysfunctions are on the rise leading to a large effect on morbidity and untimely morbidity. Cardiovascular dysfunctions are diagnosed mostly by use of ECHO which is expensive and not found in all the hospitals. Biochemical markers are affordable and can easily be done in all the hospitals. Cardiovascular risks in sickle cell disease patients using biochemical markers have not been documented locally here in Kenya